- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 09.06. | ADA: AstraZeneca's oral GLP-1 shows 'competitive efficacy' in phase 2, setting stage for pivotal program | ||
| 09.06. | Bial bails after Parkinson's fail, axing asset over phase 2 miss | ||
| 09.06. | GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancer | ||
| 08.06. | City aims to lay foundation for RNAi renaissance with nearly $100M series B | ||
| 08.06. | Clinical-stage cancer biotech Treeline sees path to public markets via reverse merger | ||
| 08.06. | J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio | ||
| 08.06. | Incyte inks $2B deal to add Star unit to late-phase constellation and challenge Takeda | ||
| 08.06. | GSK pledges £44.5M in near-term for UK biotech to explore cause of liver fibrosis regression | ||
| 08.06. | Roche bets $700M upfront on Nurix's late-phase BTK degrader to tee up Lilly showdown | ||
| 06.06. | ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes | ||
| 06.06. | ADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buy | ||
| 05.06. | Affibody gets izokibep 'back on track' while seeking 'new home' after drug's Acelyrin rejection | ||
| 04.06. | Autobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2 | ||
| 04.06. | As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too | ||
| 04.06. | Parabilis preps $413M IPO to fuel desmoid tumor drug into phase 3 | ||
| 04.06. | From business strategy to CAR-T responses, for Cabaletta it's all about 'durability' | ||
| 04.06. | Innovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC | ||
| 04.06. | Alnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer | ||
| 03.06. | Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact | ||
| 02.06. | New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells | ||
| 02.06. | Travere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases | ||
| 02.06. | ASCO: Cardiff posts updated colorectal cancer data ahead of pivotal push | ||
| 02.06. | Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks | ||
| 02.06. | Abivax stock suffers as cancer cases overshadow stellar efficacy in ulcerative colitis phase 3 trial | ||
| 02.06. | Praxis pauses one of its seizure programs after phase 2 fail |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.